The Competitive Dynamics of the Generic Drug Manufacturing Industry

Evan Hoffman ()
Additional contact information
Evan Hoffman: IBISWorld

Business Economics, 2017, vol. 52, issue 1, No 8, 68-75

Abstract: For decades, brand name drugs have been a cornerstone of growth and innovation for pharmaceutical manufacturers. In recent years, however, a combination of greater demand from the public for competitively price drugs and more frequent patent expirations has set the stage for the rise of generic drugs. The emergence of generics has tilted the competitive landscape of the industry as cheaper production costs for suppliers has had a significant impact on how industry operators interact with their supply chain. The following analysis aims to examine the competitive dynamics of the pharmaceutical sector as generics continue to flood the marketplace.

Keywords: pharma; healthcare; competition (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1057/s11369-017-0026-4 Abstract (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:buseco:v:52:y:2017:i:1:d:10.1057_s11369-017-0026-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/11369

DOI: 10.1057/s11369-017-0026-4

Access Statistics for this article

Business Economics is currently edited by Charles Steindel

More articles in Business Economics from Palgrave Macmillan, National Association for Business Economics Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().